Goat Apolipoprotein E (Apo E) Polyclonal Antibody | anti-APOE antibody

Goat anti Apo E

Cat. Num. AAA315853

• Gene Names: APOE; AD2; LPG; LDLCQ5; MGC1571
• Applications: ELISA, Western Blot
• Purity: Human Apo E-Sepharose affinity column
• Synonyms: Apolipoprotein E (Apo E); Polyclonal Antibody; Goat anti Apo E; Goat Antibody to Human Apolipoprotein E (Apo E); anti-APOE antibody

• Host: Goat
• Clonality: Polyclonal
• Specificity: Apolipoprotein E (Apo E); Binds to Apo E. Recognizes isoforms E2, E3 and E4.
• Purity/Purification: Human Apo E-Sepharose affinity column
• Form/Format: Affinity Purified, Liquid
• Concentration: 1mg/ml (OD280nm, E^0.1% = 1.35) (varies by lot)
• Sequence Length: 317

• Applicable Applications for anti-APOE antibody: EIA/ELISA, Western Blot
• Application Notes: Can be used for detection of Apo E in plasma and lipoproteins; for immunoassay (1:10,000 - 1:80,000), immunoblot (1:200 - 1:10,000), enzyme conjugation and biotinylation. Each laboratory should determine an optimum working titer for use in its particular
• Immunogen: Purified human Apo E from human plasma
• Buffer: 75mM PBS, 75mM Sodium chloride, 0.5mM EDTA, pH 7.2
• Preservative: 0.01% Sodium azide
• Important Note: Centrifuge before opening to ensure complete recovery of vial contents.
• Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0%. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.
• Preparation and Storage: Short-term store at 2 to 8 degree C. Long term store at -20 degree C. Avoid multiple freeze/thaw cycles.

Product Categories/Family for anti-APOE antibody

Polyclonal Antibodies to Lipoproteins

References

• Wassef, H., et al., (2004), "Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW872 Liposarcoma Cells", J. Nutr., 134: 2935-2941
• DeMattos, R.B., et al., (1999), "A Test of the Cytosolic Apolipoprotein E Hypo

NCBI and Uniprot Product Information

• NCBI GI #: 114039
• NCBI GeneID: 348
• UniProt Accession #: P02649; Q9P2S4; B2RC15; C0JYY5; Q13791; Q6LA97; Q6LBZ1; Q8TCZ8
• Molecular Weight: 36,154 Da
• NCBI Official Full Name: Apolipoprotein E
• NCBI Official Synonym Full Names: apolipoprotein E
• NCBI Official Symbol: APOE
• NCBI Official Synonym Symbols: AD2; LPG; LDLCQ5; MGC1571
• NCBI Protein Information: apolipoprotein E; apo-E; apolipoprotein E3; OTTHUMP00000159143; OTTHUMP00000197075; OTTHUMP00000197076; OTTHUMP00000197077
• UniProt Protein Name: Apolipoprotein E
• Protein Family: Apolipoprotein
• UniProt Gene Name: APOE
• UniProt Entry Name: APOE_HUMAN

NCBI Description

Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq]

Uniprot Description

Function: Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.

Subcellular location: Secreted.

Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle. Ref.18

Post-translational modification: Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308. Ref.19Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).Phosphorylation sites are present in the extracelllular medium.

Polymorphism: Three common APOE alleles have been identified: APOE*2, APOE*3, and APOE*4. The corresponding three major isoforms, E2, E3, and E4, are recognized according to their relative position after isoelectric focusing. Different mutations causing the same migration pattern after isoelectric focusing define different isoform subtypes. The most common isoform is E3 and is present in 40-90% of the population. Common APOE variants influence lipoprotein metabolism in healthy individuals.

Involvement in disease: Defects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [

MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. Ref.16 Ref.26 Ref.27 Ref.29Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [

MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. Ref.16Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [

MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses. Ref.16 Ref.33 Ref.36Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [

MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians. Ref.16 Ref.30 Ref.32 Ref.37

Sequence similarities: Belongs to the apolipoprotein A1/A4/E family.